On the other side of the world.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A hospital in France stopped hydroxychloroquine treatment because of cardiac side effects
Professor Émile Ferrari, the head of the cardiology department at Nice University Hospital in Nice, France, told a local news outlet he has had to stop treating patients with hydroxychloroquine combined with azithromycin because of adverse cardiac effects.
Nice University Hospital was selected as part of a trial to test some coronavirus treatments, including hydroxychloroquine. Ferrari told Nice-Matin newspaper that one patient experienced a serious complication and that the treatment was stopped immediately.
The cardiologist reiterated what health experts have warned about the drug combination: that the drugs can trigger arrhythmia, which can lead to a fatal heart attack in some patients, especially those who have heart conditions or are on certain medications.
In the United States, doctors have recommended screening patients with an electrocardiogram to prevent the drugs from being given to the 1 percent of patients at greatest risk of a cardiac event, The Washington Post has reported. The drugs also can cause vision loss called retinopathy with long-term use, and chloroquine has been associated with psychosis.
So far, there is no clear evidence that the drugs work to treat the coronavirus, though their antiviral properties have been tested in labs. Rigorous clinical trials that test the drugs in humans against placebos have not been completed.
Ferrari told Nice-Martin that although covid-19 can kill, the treatment should not be more harmful than the disease.
https://www.washingtonpost.com/world/2020/04/07/coronavirus-latest-news/#link-K4DJOFMFVVBEPGPHM2NFG3A4BI
The country doctor didn’t test any patients for Covid-19. They were also mild respiratory cases with no control group.
The small French study dropped and didn’t include 4 patients with severe symptoms one of whom died. Add those back in and you have pretty much the same numbers one would expect without treatment: 80% mild to moderate, 20% severe, 1 patient death.
I agree, it all goes very slowly. But, SARS-CoV is a tough one. Labs at universities and biopharmas have been working on a treatment and vaccine for more than 30 years. With this outbreak and pandemic we are 2 months into world contagion and a month following emergency research funding. If something currently in testing is going to emerge as a treatment, it will happen in the next 2 months.
Just for the record, after 15 years of quinines killing SARS in cell cultures, I doubt it will be anything currently strategic stockpiling.
Try it how? Injection? Enema? Oral rinse? Those are the current proven delivery methods. It’s possible that an IV , circulatory system, won’t deliver sufficient B to the infection site. For oral rinse and enema, there was no systemic absorption. B worked because it was delivered directly to the inflamed site. So, it’s quite possible that IV delivery would not deliver B from circulation across alveoli to inflamed Interior surface cells.
Let the labs work out the delivery through testing, otherwise should there be right to try, there is a high risk of setbacks (perceived failure) due to inefficient delivery method.
Your link leads to an error message: NCT Number not Found
“Study NCT00205238 does not exist in ClinicalTrials.gov.
Please check that your ClinicalTrials.gov Identifier (NCT Number) is correct.”
RP: I’m suggesting a head of state has no medical background and promotes things manufactured by loyalists. IPIX and Leo don’t contribute to reelection campaigns (that I know of).
Also Scottsmith, please note the date of that paper: Virol J. 2005; 2: 69.
Published online 2005 Aug 22.
The article is 15 years old and Chloroquine is still not the standard of care for SARS. Real promising.
From your reference: “ Chloroquine is effective in preventing the spread of SARS CoV in cell culture.“
Cell culture is hardly great scientific underpinning. Brilacidin is also effective “in cell culture” as reported last week. But, what about humans at therapeutic concentrations? Malarial blood parasites are not the same as coronaviral alveoli cell infection.
Then what was all that happy crap yesterday? Still on that side of the trade? Rhetorical question.
First, this makes no sense. Second what is your point? Just say it.
I see you’re on the other side of the trade. Yesterday it was all bowls of roses, today it’s “never ending cycles” of gloom.
Yes, but need to elaborate on your time line:
There won’t be a vaccine for 12-18 months, if then. This is the third epidemic of coronavirus in 20 years, yet there is still no vaccine. The minimum is 12 months, but most probably longer.
An effective treatment can be approved before end of summer, maybe a little sooner. The malaria drug will take a few months. We will know hw long by end of May, if it works in controlled trial. Brilacidin will take a little longer since it has an established safety profile, but is only phase 3 ready. It will take a few months longer.
Maybe I was too subtle. Your questions are exactly those under discussion. They will be answered in the next day or two.
A couple of hours, is my guess. The question is are they today or tomorrow?
I’m suggesting a head of state has no medical background and promotes things manufactured by loyalists. IPIX and Leo don’t contribute to reelection campaigns (that I know of).
Um...because that is what they are still discussing? Just another (rhetorical) question.
Um... because they are still in discussions over what those next steps should be? Just a (rhetorical) question.
It’s paid entirely by others who are well-funded.
I thought it was clear: they want B if it works. Same as the crap heads of state are pushing. Need positive proof. And B may or may not advance quickly to rapid human trials. One barrier, the crap promoted by a head of state is sucking up all the oxygen.
News. Not great news but news. Brilacidin advances into discussions to advance.
NEWS: Innovation Pharmaceuticals in Discussions to Advance Brilacidin into Human Trials Against COVID-19
WAKEFIELD, MA – April 6, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB: IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today the Company is engaged in discussions with health care provider networks and hospitals both in the United States and Europe regarding options to rapidly advance Brilacidin testing into human trials to evaluate its potential as a novel coronavirus (COVID-19) therapeutic.
Their interest in Brilacidin as a treatment for COVID-19 and associated complications is based on the drug’s promising antiviral activity against SARS-CoV-2, as supported in preliminary testing conducted in a monkey epithelial cell line and its established anti-inflammatory and antimicrobial properties—a potential 3-in-1 treatment combination. In advance of potential clinical testing, the Company is investigating procurement of appropriate drug supply (i.e., manufacture of intravenous drug product), and preparing for engagement with regulatory authorities. There can be no assurance that any Brilacidin for COVID-19 clinical trial will commence.
Concurrently, laboratory testing of Brilacidin against SARS-CoV-2, the novel coronavirus responsible for COVID-19, will continue. This is based on recommendations made by the lead researcher at one of the U.S. Regional Biocontainment Laboratories (RBLs) who performed preliminary testing of Brilacidin. Results were characterized as “extremely encouraging.” Immediate next steps include conducting studies in human lung cells, exploring dosing and evaluating the drug’s effect on the viral envelope.
If you are going to discuss US and world politics, please relate it to IPIX. Mentioning “go IPIX” in a post is not relating the subject of the post to IPIX, Brilacidin or SARS-CoV. Thanks.
IPIX Receives Data for Direct Inhibition of SARS-CoV-2,
the Novel Coronavirus Responsible for COVID-19
WAKEFIELD, MA – April 1, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today it has received data supporting Brilacidin’s direct inhibition of SARS-CoV-2, the novel coronavirus responsible for COVID-19. The testing of Brilacidin was conducted by researchers at one of the U.S. Regional Biocontainment Laboratories (RBLs). Few compounds have shown activity against SARS-CoV-2, as summarized in the article linked below.
Andersen P, et al. “Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents.” Int J Infect Dis. 2020 Feb 17;93:268-276. doi: 10.1016/j.ijid.2020.02.018.
https://www.sciencedirect.com/science/article/pii/S120197122030076X
https://ars.els-cdn.com/content/image/1-s2.0-S120197122030076X-gr5.jpg
VERO cells, a monkey kidney cell line commonly used to screen small molecule inhibitors of viruses, were used to test whether Brilacidin inhibits SARS-CoV-2. Cells were pretreated with Brilacidin at increasing concentrations (at 2 µM and at 10 µM) for two hours prior to the infection. Cells treated with the vehicle alone (Dimethyl sulfoxide or DMSO) were maintained alongside, as controls. At 16 hours post-infection (16hpi), researchers observed a dose-dependent reduction in the SARS-CoV-2 infectious viral titers from the Brilacidin treated cells as compared to the vehicle-alone control, as shown below. (The higher number of asterisks denote higher statistical significance compared to control.)
RBL Figure 1
The Company is reviewing data received yesterday and anticipates more data will be forthcoming. Following discussions with researchers at the RBL, the Company will provide additional information and insight into possible joint research plans going forward. It is management’s understanding that few compounds advance to this next stage of SARS-CoV-2 research.
In a broader context, demonstration of Brilacidin’s direct antiviral activity against the SARS-CoV-2 virus supports the drug’s unique 3-in-1 therapeutic potential—antiviral, anti-inflammatory, antimicrobial—to treat COVID-19 and its associated complications. Additional data, based on successfully completed Phase 2 clinical studies in other clinical indications, using various modes of administration, show Brilacidin’s ability to inhibit interleukin-6 (IL-6) and other pro-inflammatory cytokines and chemokines, identified as central drivers in the worsening prognoses of COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help fight secondary bacterial infections, which can co-present in patients with COVID-19
Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19
WAKEFIELD, MA – April 1, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today it has received data supporting Brilacidin’s direct inhibition of SARS-CoV-2, the novel coronavirus responsible for COVID-19. The testing of Brilacidin was conducted by researchers at one of the U.S. Regional Biocontainment Laboratories (RBLs). Few compounds have shown activity against SARS-CoV-2, as summarized in the article linked below.
Andersen P, et al. “Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents.” Int J Infect Dis. 2020 Feb 17;93:268-276. doi: 10.1016/j.ijid.2020.02.018.
https://www.sciencedirect.com/science/article/pii/S120197122030076X
https://ars.els-cdn.com/content/image/1-s2.0-S120197122030076X-gr5.jpg
VERO cells, a monkey kidney cell line commonly used to screen small molecule inhibitors of viruses, were used to test whether Brilacidin inhibits SARS-CoV-2. Cells were pretreated with Brilacidin at increasing concentrations (at 2 µM and at 10 µM) for two hours prior to the infection. Cells treated with the vehicle alone (Dimethyl sulfoxide or DMSO) were maintained alongside, as controls. At 16 hours post-infection (16hpi), researchers observed a dose-dependent reduction in the SARS-CoV-2 infectious viral titers from the Brilacidin treated cells as compared to the vehicle-alone control, as shown below. (The higher number of asterisks denote higher statistical significance compared to control.)
RBL Figure 1
The Company is reviewing data received yesterday and anticipates more data will be forthcoming. Following discussions with researchers at the RBL, the Company will provide additional information and insight into possible joint research plans going forward. It is management’s understanding that few compounds advance to this next stage of SARS-CoV-2 research.
In a broader context, demonstration of Brilacidin’s direct antiviral activity against the SARS-CoV-2 virus supports the drug’s unique 3-in-1 therapeutic potential—antiviral, anti-inflammatory, antimicrobial—to treat COVID-19 and its associated complications. Additional data, based on successfully completed Phase 2 clinical studies in other clinical indications, using various modes of administration, show Brilacidin’s ability to inhibit interleukin-6 (IL-6) and other pro-inflammatory cytokines and chemokines, identified as central drivers in the worsening prognoses of COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help fight secondary bacterial infections, which can co-present in patients with COVID-19
Since I believe Leo would never publicize a trial end and future release of results without knowing the preliminary outcomes, B showed efficacy against CoV-2 in culture and will move to the next phase of testing. These results were too fast for in vivo studies examining both efficacy against CoV-2 infection as well as efficacy against inflammation. But, the next announcement will probably be approval to advance. Hopefully that will mean limited human testing, but could also be formulation for delivery followed by mouse or other quick, preclinical protocol.
As discussed last week, $8 billion was approved for CoV research and drug development. There is nothing more authorized in the $2 trillion stimulus, that I have been able to find. The new House bill aims at shoring up hospital shortfalls, patient treatments and more distressed family giveaways. Nothing more for research that I know of.
It doesn’t last 2 to 4 weeks. It lasts 3 to 6 weeks, or more. From onset of symptoms the average time for those who die is 30 days. Symptoms last 2 weeks for younger patients with mild cases and goes up to 8 weeks for those who suffer severe respiratory distress. That would be 20% of all cases.
FWIW, current mortality in the USA was at 1.1% 2 weeks ago, but as of today has climbed to 2.4%. That’s because confirmed coronavirus subjects have doubled twice in 2 weeks, but it takes 30 days or more for respiratory distress to become terminal. Things will get worse in the next 2 weeks. It now looks like the original mortality of 2-3% was correct. Fauci’s 1% was actually best case even though it is 10 times the rate the president had been quoting up until last week.
“ WGAF about Hydroxychloroquine?“
The folks who will be testing it clinically against coronavirus in a controlled trial. As Anthony Fauci pointed out, currently the evidence is anecdotal, including the stuff that has been published.
This is the bill I’m talking about. https://www.npr.org/2020/03/04/812109864/bipartisan-negotiators-reach-deal-for-roughly-8-billion-for-coronavirus-response
The current $1.8 trillion bill is a business and government stimulus package. The sticking point is a lack of provisions demanding business money guarantees no layoffs and can’t be used for stock buybacks. Also, like the previous two stimulus packages, the ones in 2001 and 2009, the beneficiaries must be chosen by a select committee of experts and not by the secretary of the treasury, as the bill is currently written.
The bill that failed to pass yesterday is the 1.8 trillion dollar stimulus bill that is mostly loans and aid to small and large businesses. The bill to fund pharmaceuticals with $8 billion passed a while ago.
It is just a bad flu if you consider 12 to 15 times (in the US) as deadly a “bad flu.” In Italy, for some reason, it’s 30 to 50 times as deadly.
There is this notion that Covid-19 only affects old people. Not true. For many under 45 it is like the worst flu you ever had as symptoms include respiratory distress and recovery can last up to 6 weeks. Again, in Italy (and now France) Covid-19 is knocking-off large numbers of men under 45.
I’m saying it’s an over the counter drug as well as doctors are prescribing therapeutic formulations to those who don’t need it. I’m saying people are panic buying drugs the same as toilet paper and hand sanitizer.
“ IMO Doubt anyone will be without it if they need it.”
People who need it are already without it because it is being promoted as a possible treatment. People are buying up supples the same way they are buying up toilet paper and hand sanitizer, but with less reliable evidence of the need. Meanwhile, those dependent on the drugs are already going without.
My response: "Hydroxychloroquine is especially important for people with lupus, which can be life-threatening, Dr. Lockshin said. The drug can lower the risk of dying from lupus and prevent organ damage, and is considered the standard of care. If patients stop taking it after using it regularly for a long time, they can gradually become quite ill. He said it was particularly disturbing to think that people known to benefit from the drug could lose access to it because it is being diverted to a disease for which there is no solid evidence that it actually works."
https://www.nytimes.com/2020/03/20/health/coronavirus-chloroquine-trump.html?action=click&module=Well&pgtype=Homepage§ion=Health
“ There are no cases being reported in Africa because they are very poor and have had almost no test kits.“
Bingo. Exactly right. They also do not have direct flights with China.
There is no reliable evidence of its efficacy. It’s all nonsense from leaders with no understanding of science, in spite of what they self-promote. A cell membrane is not a virion shell.
That there is no Covid-19 in Africa has nothing to do with its efficacy against a virus. Malaria is a relatively large parasite, while coronavirus is 1000 times smaller. And a completely different structure. Coronavirus has a shell, malaria has a cell membrane.
hydroxychloroquine Is a scam cooked up by its IP holders and those looking for a quick profit. There is very little evidence it works on coronavirus other than Trump mentioned it. Trump has no understanding of any science other than what can be promoted as a possible treatment for his own profit.
Well, looks like testing focuses on MOA against Covid and no one wants to move into trials against Covid until after all preliminary work. That really surprises me since the CDC and FDA have been boasting about faster process. But, what I see of the latest pandemic emergency treatment development seems much more cumbersome than previous outbreaks from the past 30 years. If there was a potential treatment already finished animals and successfully through phase 2 safety with high tolerance, then under emergency protocols, it was given to a few patients.
Death panels happen anyway. If/when Covid-19 cases exceed 500,000 cases, that will mean there will be About 100,000 severe Covid-19 patients requiring ventilators. There are estimated 66,000 to 72,000 ventilators including those in the strategic stockpile. Who do you think will decide which patients will be treated with the device and which won’t? A bureaucrat in the hospital system will work with doctors saying who will get it and who won’t. Death panels happen all the time in extreme conditions. It’s part of the process of triage when facilities, equipment and treatments are limited. That’s what’s happening in Italy.